573764-31-5

Basic information

• Product Name: 4-CHLORO-3-IODOANILINE
• Synonyms: 4-CHLORO-3-IODOANILINE;4-Chloro-3-iodoaniline 97%;BenzenaMine, 4-chloro-3-iodo-;4-Chloro-3-iodo-phenylamine;4-Chloro-3-iodoaniline97%
• CAS NO: 573764-31-5
• Molecular Formula: C₆H₅ClIN
• Molecular Weight: 253.47
• Mol File: 573764-31-5.mol
• Article Data: 11

Chemical Properties

• Melting Point: 70 °C
• Boiling Point: 322.297 °C at 760 mmHg
• Flash Point: 148.72 °C
• Appearance: /
• Density: 2.016 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.00±0.10(Predicted)
• CAS DataBase Reference: 4-CHLORO-3-IODOANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-3-IODOANILINE(573764-31-5)
• EPA Substance Registry System: 4-CHLORO-3-IODOANILINE(573764-31-5)

Safety Data

• Hazardous Substances Data: 573764-31-5(Hazardous Substances Data)

Usage

General Description

4-CHLORO-3-IODOANILINE is a chemical compound with the molecular formula C6H5ClIN. It is a halogen-substituted aniline that is commonly used in the synthesis of various pharmaceuticals, agrochemicals, and dyes. 4-CHLORO-3-IODOANILINE is considered to be mildly toxic, and can cause irritation to the skin, eyes, and respiratory tract upon exposure. It is also considered to be a potential environmental hazard, as it is persistent in soil and water. Therefore, proper handling and disposal methods should be followed when working with 4-CHLORO-3-IODOANILINE to minimize its impact on human health and the environment.

Upstream product

• 62-53-3 aniline 
• 106-47-8 4-chloro-aniline 
• 100-00-5 4-chlorobenzonitrile 
• 6283-25-6 H₂NC₆H₃(Cl)NO₂ 
• 74534-15-9 1-chloro-2-iodo-4-nitrobenzene 
• 7439-89-6 iron 
• 32337-97-6 1-chloro-2-iodo-3-nitrobenzene 

Downstream Products

• 879088-63-8 5-Acetyl-N-(4-chloro-3-iodophenyl)thiophene-2-carboxamide 
• 1552310-58-3 ethyl 2-(3-chloro-4-(4-chloro-3-(pyridin-2-yl)phenylcarbamoyl)phenyl sulfonamido)pyrimidine-5-carboxylate 
• 879088-41-2 4-chloro-3-(pyridin-2-yl)benzeneamine 
• 1552310-67-4 tert-butyl 4-((3-chloro-4-(4-chloro-3-(pyridin-2-yl)phenylcarbamoyl)phenyl sulfonamido)methyl)piperidine-1-carboxylate 
• 1552310-69-6 ethyl 2-(4-((3-chloro-4-(4-chloro-3-(pyridin-2-yl)phenylcarbamoyl)phenyl sulfonamido)methyl)piperidin-1-yl)pyrimidine-5-carboxylate 
• 1552310-98-1 ethyl 4-(2-(3-chloro-4-(4-chloro-3-(pyridin-2-yl)phenylcarbamoyl)phenyl sulfonamido)ethoxy)benzoate 
• 1552310-33-4 (E)-methyl-3-(6-(2-chloro-5-(2-chloro-4-(methylsulfonyl)benzamido)phenyl)pyridin-3-yl)acrylate 
• 879085-55-9 vismodegib 
• 1314306-02-9 2-chloro-N-(4-chloro-3-iodophenyl)-4-methylsulfonylbenzamide 
• 56970-25-3 6-chloro-[1,1'-biphenyl]-3-amine 

Relevant articles and documents

AN IMPROVED ONE POT, ONE STEP PROCESS FOR THE HALOGENATION OF AROMATICS USING SOLID ACID CATALYSTS

The present invention disclosed an improved one pot, one step process for halogenation of compound of formula (II) to afford corresponding halogenated compound of formula (I) having improved yield and increased selectivity under very mild conditions.

Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity

Medulloblastoma is one of the most prevalent brain tumors in children. Aberrant hedgehog (Hh) pathway signaling is thought to be involved in the initiation and development of medulloblastoma. Vismodegib, the first FDA-approved cancer therapy based on inhibition of aberrant hedgehog signaling, targets smoothened (Smo), a G-protein coupled receptor (GPCR) central to the Hh pathway. Although vismodegib exhibits promising therapeutic efficacy in tumor treatment, concerns have been raised from its nonlinear pharmacokinetic (PK) profiles at high doses partly due to low aqueous solubility. Many patients experience adverse events such as muscle spasms and weight loss. In addition, drug resistance often arises among tumor cells during treatment with vismodegib. There is clearly an urgent need to explore novel Smo antagonists with improved potency and efficacy. Through a scaffold hopping strategy, we have identified a series of novel tetrahydropyrido[4,3-d]pyrimidine derivatives, which exhibited effective inhibition of Hh signaling. Among them, compound 24 is three times more potent than vismodegib in the NIH3T3-GRE-Luc reporter gene assay. Compound 24 has a lower melting point and much greater solubility compared with vismodegib, resulting in linear PK profiles when dosed orally at 10, 30, and 100 mg/kg in rats. Furthermore, compound 24 showed excellent PK profiles with a 72% oral bioavailability in beagle dogs. Compound 24 demonstrated overall favorable in vitro safety profiles with respect to CYP isoform and hERG inhibition. Finally, compound 24 led to significant regression of subcutaneous tumor generated by primary Ptch1-deficient medulloblastoma cells in SCID mouse. In conclusion, tetrahydropyrido[4,3-d]pyrimidine derivatives represent a novel set of Smo inhibitors that could potentially be utilized to treat medulloblastoma and other Hh pathway related malignancies.

HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES

The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The com-pounds can be used in methods of treating proliferative dis-eases and disorders such as cancer